chufangao/CTO huggingface dataset:
Clinical trial NCT03378466: Heparin Anticoagulation in Septic Shock
Official title: Heparin AnticoaguLation to Improve Outcomes in Septic Shock: The HALO International Phase II RCT
Acronym: HALO
Sponsor: University of Manitoba (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: infeasible to continue due-to inability to recruit during the COVID-19 pandemic and grants coming to an end.
Enrollment: 178.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-12
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT04350086: Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection
Official title: Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection
Acronym: PRODEX
Sponsor: University Hospital, Limoges (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: unfavorable opinion of the ethics committee
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-20
Primary completion date: 2020-11-20
Completion date: 2020-11-20
Plan to share individual participant data: NO
Clinical trial NCT03657160: Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 343.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-06
Primary completion date: 2022-02-07
Completion date: 2022-05-09
Baseline population: Full Analysis Set (FAS) included all participants who were randomized, received at least 1 dose of the treatment, and under-went allo-HSCT.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT02129348: Treatment of Psychosis and Agitation in Alzheimer's Disease
Official title: Treatment of Psychosis and Agitation in Alzheimer's Disease
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 77.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-06-30
Primary completion date: 2020-01-31
Completion date: 2020-01-31
Clinical trial NCT03205553: Direct Peritoneal Resuscitation in Gastroschisis
Official title: Direct Peritoneal Resuscitation in Gastroschisis
Sponsor: University of Arkansas (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: COVID-19 pandemic
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-01
Primary completion date: 2018-05-02
Completion date: 2020-10-21
Plan to share individual participant data: NO
Clinical trial NCT05312697: Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
Official title: A Phase 2b, Multicenter, Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
Sponsor: Ultragenyx Pharmaceutical Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision not related to safety concerns
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-28
Primary completion date: 2022-07-07
Completion date: 2022-07-07
Plan to share individual participant data: NO
Clinical trial NCT03629249: Systemic Corticosteroids Avoidance Study in Severe Asthma Patients
Official title: A 52-week, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Reduction of Systemic Corticosteroids (Oral and Parenteral) Use in Patients With Severe Asthma
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Company decision
Enrollment: 604.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-12-13
Primary completion date: 2020-02-06
Completion date: 2020-02-06
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT03561883: Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors
Sponsor: Ironwood Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 609.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-06
Primary completion date: 2020-07-28
Completion date: 2020-11-06
Baseline population: Safety Population: Participants who received at least 1 dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT05953545: Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis
Official title: Open Label Phase 2 Clinical Study of Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study closure based on decision of the PI
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2024-05-22
Primary completion date: 2024-05-22
Completion date: 2024-05-22
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03603314: Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
Official title: A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
Acronym: AUDIBLE-S
Sponsor: Sensorion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 115.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-02-15
Primary completion date: 2021-11-04
Completion date: 2022-01-12
Clinical trial NCT03265977: A Phase II Study of H56:IC31 in Healthy Adolescents
Official title: A Randomized, Placebo Controlled, Double-Blind Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis (Mtb) of H56:IC31 in Healthy Adolescents
Acronym: A-043
Sponsor: Aeras (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Design, sponsorship changed prior to initiation. No study procedures done.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-30
Primary completion date: 2021-04-30
Completion date: 2021-06-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02707978: F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)
Official title: F 18 T807 Tau PET Imaging of Frontotemporal Dementia
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Problems with contracts .
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-30
Primary completion date: 2020-09-30
Completion date: 2020-12-30
Clinical trial NCT02549092: A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
Official title: An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 89.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-10-26
Primary completion date: 2020-05-14
Completion date: 2022-11-18
Baseline population: Safety dataset: all participants randomized to OMT, and all participants randomized to LCIG who had study device (NJ and/or PEG-J) placement.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT03889756: Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy
Official title: Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy
Acronym: SAD-KIDS
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: No more funding available to continue since we could not recruit throughout the pandemic.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-17
Primary completion date: 2019-12-18
Completion date: 2023-01-05
Baseline population: Demographic data will be presented together to avoid unblinding of subjects due to small number of participants
Limitations and caveats: The study was only able to enroll 3 participants before the pandemic started and then ran out of funding to finish the trial. Presented are summary data and to avoid revealing any identifying information of participants, data is presented overall where applicable (e.g. baseline characteristics).
Clinical trial NCT05076253: Efficacy of Ivermectin in COVID-19
Official title: Efficacy and Safety of Ivermectin in Treatment of Mild to Moderate COVID-19 Infection: a Randomized ,Double Blind,Placebo,Controlled Trial
Sponsor: Bangkok Metropolitan Administration Medical College and Vajira Hospital (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 72.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-01
Primary completion date: 2021-12-01
Completion date: 2021-12-01
Plan to share individual participant data: YES
IPD sharing description: Data will be made available upon request after publication
IPD time frame: After publication
Clinical trial NCT02343549: A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Official title: A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: closed to accrual due to low accrual
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-01-31
Primary completion date: 2020-07-11
Completion date: 2020-07-11
Clinical trial NCT04166552: Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis
Official title: A Phase IIa, Double-Blind, Randomised, Intracohort Placebo-Controlled, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients With Diffuse Cutaneous Systemic Sclerosis
Sponsor: Emerald Health Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Sponsor ceasing all operations due to company's shut down
Enrollment: 36.0 (ESTIMATED)
Number of arms: 4.0
Start date: 2020-06-11
Primary completion date: 2024-07-31
Completion date: 2024-10-31
Plan to share individual participant data: NO
Clinical trial NCT05119439: Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks
Official title: An Outpatient Medical Abortion Regimen With Mifepristone and Two Doses of Misoprostol at 71-77 and 78-84 Days of Pregnancy
Sponsor: Gynuity Health Projects (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Enrollment
Enrollment: 23.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-07
Primary completion date: 2023-06-30
Completion date: 2023-06-30
Clinical trial NCT04460105: Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
Official title: A Phase 1b, Randomized, Double-blind, Single and Repeat Dosing Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab When Added to Standard-of-Care in Subjects Hospitalized With COVID-19 Pneumonia
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study was withdrawn due to challenges in site recruitment and lack of patient enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-31
Primary completion date: 2021-01-27
Completion date: 2021-01-27
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT03661528: Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
Official title: A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor
Sponsor: Alexion Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 530.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-06
Primary completion date: 2023-05-27
Completion date: 2023-08-09
Baseline population: Measured in the Intent-to-Treat Population (ITT), Extended Population, which included all randomized participants according to the randomized treatment.
Clinical trial NCT03613259: Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma
Official title: A Pilot Study Investigating ¹⁸F-FLT-PET as a Marker of Response to Preoperative Radiotherapy in Soft Tissue Sarcoma
Sponsor: OHSU Knight Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Funding expired
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-01
Primary completion date: 2022-06-01
Completion date: 2022-06-01
Clinical trial NCT03004105: MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
Official title: Phase II Trial of Immunotherapy With Durvalumab (MEDI4736) With Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Inadequate funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-05-31
Primary completion date: 2023-05-31
Completion date: 2024-05-31
Clinical trial NCT03733925: A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
Official title: A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
Sponsor: Johnson & Johnson Private Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-07
Primary completion date: 2021-11-15
Completion date: 2021-11-15
Clinical trial NCT05703308: Menstrual Blood Stem Cells in Poor Ovarian Responders
Official title: Outcome of Pregnancy in Poor Ovarian Responders by Intraovarian Administration of Autologous Menstrual Blood Derived-Mesenchymal Stromal Cells
Sponsor: Avicenna Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 180.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-21
Primary completion date: 2021-09-22
Completion date: 2022-10-22
Clinical trial NCT00924326: CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Official title: An Assessment of the Safety and Feasibility of Administering T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With B-Cell Lymphoma
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 43.0 (ACTUAL)
Number of arms: 10.0
Start date: 2009-02-17
Primary completion date: 2015-09-30
Completion date: 2021-11-17
Plan to share individual participant data: NO
Clinical trial NCT02770820: Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia
Official title: Phase I/II Study of Autologous (Central Memory/Naïve) CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of AML
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated due to funding difficulties
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-11-06
Primary completion date: 2020-06-01
Completion date: 2020-06-01
Clinical trial NCT03900624: Ideal Steroids for Asthma Treatment in the PICU
Official title: Ideal Steroids for Asthma Treatment in the PICU (iSTAT PICU): A Prospective, Comparative, Single-arm Study Assessing Dexamethasone Versus Methylprednisolone in Severe Status Asthmaticus Admitted to the Pediatric Intensive Care Unit
Acronym: iSTAT PICU
Sponsor: Johns Hopkins All Children's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 92.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-21
Primary completion date: 2021-12-31
Completion date: 2022-05-15
Plan to share individual participant data: NO
Clinical trial NCT03744715: A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
Official title: An Open-Label Extension Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
Sponsor: Spectrum Pharmaceuticals, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business reasons, not related to safety.
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-05
Primary completion date: 2023-03-03
Completion date: 2023-03-03
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02648347: Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
Official title: Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CORRECTION)
Sponsor: Akebia Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1751.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-31
Primary completion date: 2020-06-04
Completion date: 2020-07-31
Plan to share individual participant data: NO
Clinical trial NCT03287050: Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
Official title: FAST: Feasibility Trial of Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: due to changing therapeutic landscape in metastatic bladder cancer and lack of radiation/immunotherapy systemic synergy in other malignancies
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-01-24
Primary completion date: 2019-03-13
Completion date: 2020-11-10
Limitations and caveats: This study was closed early (at 6 patients) due to changing therapeutic landscape in metastatic bladder cancer and lack of radiation/immunotherapy systemic synergy in other malignancies.
Clinical trial NCT03025880: Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC
Official title: A Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Pembrolizumab and Gemcitabine in Patients With HER2-negative Advanced Breast Cancer (ABC) PANGEA-Breast
Acronym: PANGEA
Sponsor: Spanish Breast Cancer Research Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-28
Primary completion date: 2019-06-03
Completion date: 2021-07-22
Plan to share individual participant data: NO